News | May 04, 2026
Moderna posts Q1 2026 loss despite revenue surge
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Funds to support product expansion, quick commerce growth, and manufacturing scale-up for holistic period care solutions
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
Hospital project inaugurated by Devendra Fadnavis aims to strengthen healthcare access across North Maharashtra and nearby regions
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
The initiative pairs consumer engagement with a public health message about prevention and early detection
Lifts full-year outlook as obesity drug boom accelerates
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The company posted revenue of €1,267 million, up 6% on a constant currency basis
Subscribe To Our Newsletter & Stay Updated
